Listen to this pre-recorded podcast to learn from Dr. Ehsan Malek, a hematologist oncologist at Roswell Park, about some of the major breakthroughs in CAR T therapy in 2024 and what is on the horizon in 2025.

Dr. Kathryn Lurain shares about the advancements in HIV-associated DLBCL treatment, covering research, challenges, and future directions.

Dr. Strati shares about trials happening at MD Anderson for DLBCL and follicular lymphoma. This includes the following:

Two completed follicular lymphoma trials: 

Phase I study of evorpacept and R2 in relapsed indolent B-NHL

Phase 2 study of acalabrutinib and R2 in previously untreated indolent B-NHL

One ongoing DLBCL trial:

Phase 2 study of loncastuximab as consolidation after CART in DLBCL

One upcoming DLBCL trial:

Phase 2 study of emapalaumab for the treatment of persistent severe cytopenia after CART in DLBCL

Dr. Melani discusses the latest updates from the VVIP, VIPOR, and VIPOR-P studies, which are clinical trials for non-Hodgkin's lymphoma. The goal of these studies is to improve the outcome for patients with relapsed or refractory lymphomas by using targeted therapy combinations. The targeted therapies block specific proteins that cancer cells need to grow and survive. The conversation also discusses these three clinical trials' design and treatment protocols.

Defining and tracking progression/remission in DLBCL patients can be subjective and complicated. In this episode, we are joined by Dr. Juan Pablo Alderuccio, a lymphoma specialist at the University of Miami. Dr. Alderuccio recently published his research on PET-based biomarkers in lymphoma patients. His research aims to give patients a more accurate knowledge of their lymphoma prognosis.

Thank you to our episode sponsor, Regeneron.